Doses of hepatitis B revaccination needed for the seronegative youths to be seropositive to antibody against hepatitis B surface antigen.


Journal

Family practice
ISSN: 1460-2229
Titre abrégé: Fam Pract
Pays: England
ID NLM: 8500875

Informations de publication

Date de publication:
19 02 2020
Historique:
pubmed: 4 8 2019
medline: 23 3 2021
entrez: 4 8 2019
Statut: ppublish

Résumé

To determine the required hepatitis B vaccine doses for subjects who were seronegative for three hepatitis B seromarkers during their youth who wish to have seroprotective antibodies against the hepatitis B surface antigen (anti-HBs). We conducted a retrospective cohort study. From 2012 to 2015, graduate school students born after 1986 who were seronegative for three hepatitis B virus seromarkers at college entrance (n = 1037) were recruited. Four groups of subjects received zero to three doses of a hepatitis B vaccine booster at their free willingness, and their anti-HBs titre were measured at their graduate school entrance. Very low and extremely low antibody titres against the hepatitis B surface antigen were elucidated by graphic inference to determine the required booster dose cut-off value for seropositivity after revaccination. The anti-HBs seropositive rates in the four groups of subjects receiving the hepatitis B booster vaccine(s) were 17.7%, 52.1%, 78.6% and 90.9% for those receiving zero, one, two and three doses, respectively. In subjects with very low antibody titres against the hepatitis B surface antigen after one dose of the vaccine booster and subjects with an extremely low titre after two doses of the booster, the seropositive rates reached 95% at the cut-off value of 3 mIU/ml. A seropositive rate of at least 95% can be reached by the administration of two hepatitis B booster doses to youths with extremely low antibody titres against the hepatitis B surface antigen (<3 mIU/ml) and administering one dose to those with very low titres (3-10 mIU/ml) at college.

Identifiants

pubmed: 31375819
pii: 5543276
doi: 10.1093/fampra/cmz039
doi:

Substances chimiques

Hepatitis B Antibodies 0
Hepatitis B Surface Antigens 0
Hepatitis B Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-35

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press.

Auteurs

Chyi-Feng Jan (CF)

Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

Tzu-Hung Liu (TH)

Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Chien-Han Ho (CH)

Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Yin-Chu Chien (YC)

Genomics Research Center, Academia Sinica, Taipei, Taiwan.

Che-Jui Chang (CJ)

Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Fei-Ran Guo (FR)

Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Kuo-Chin Huang (KC)

Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH